Psychometric Hepatic Encephalopathy Score in Prediction of Minimal Hepatic Encephalopathy in Compensated Cirrhotic Patients
NCT ID: NCT07272707
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
150 participants
OBSERVATIONAL
2025-12-01
2026-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Minimal Hepatic Encephalopathy in Patients With Cirrhosis and Portal Hypertension
NCT04807803
A Study of MHE in Patients With Liver Diseases
NCT04058327
Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)
NCT05140837
Development of a Cognitive Tool for Rapid and Reliable Screening of Minimal Hepatic Encephalopathy: Pilot Study
NCT06619106
Correlation Between Serum Albumin Level and Severity of Hepatic Encephalopathy in Patients With Chronic Liver Disease in Sohag University Hospital
NCT06953921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 2: Healthy Volunteers (Controls)
Healthy adults aged 18-70 years with no chronic disease and normal cognitive function undergoing Psychometric hepatic encephalopathy score testing.
Psychometric Hepatic Encephalopathy Score (PHES)
A standardized paper-and-pencil neuropsychological test battery used to detect minimal hepatic encephalopathy. It includes:
1. Number Connection Test A (NCT-A)
2. Number Connection Test B (NCT-B)
3. Digit Symbol Test (DST)
4. Serial Dotting Test (SDT)
5. Line Tracing Test (LTT)
Tests are administered in a quiet environment between 8 AM and 3 PM by trained personnel. Performance is recorded as completion time, error score, or point score depending on test type.
Group 1: Cirrhotic Patients (Cases)
Compensated cirrhotic patients aged 18-70 years undergoing Psychometric hepatic encephalopathy score testing.
Psychometric Hepatic Encephalopathy Score (PHES)
A standardized paper-and-pencil neuropsychological test battery used to detect minimal hepatic encephalopathy. It includes:
1. Number Connection Test A (NCT-A)
2. Number Connection Test B (NCT-B)
3. Digit Symbol Test (DST)
4. Serial Dotting Test (SDT)
5. Line Tracing Test (LTT)
Tests are administered in a quiet environment between 8 AM and 3 PM by trained personnel. Performance is recorded as completion time, error score, or point score depending on test type.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Psychometric Hepatic Encephalopathy Score (PHES)
A standardized paper-and-pencil neuropsychological test battery used to detect minimal hepatic encephalopathy. It includes:
1. Number Connection Test A (NCT-A)
2. Number Connection Test B (NCT-B)
3. Digit Symbol Test (DST)
4. Serial Dotting Test (SDT)
5. Line Tracing Test (LTT)
Tests are administered in a quiet environment between 8 AM and 3 PM by trained personnel. Performance is recorded as completion time, error score, or point score depending on test type.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosed compensated liver cirrhosis, regardless of etiology.
3. Able to read and write.
4. Adequate vision, hearing, and physical ability to perform the PHES tests.
<!-- -->
1. Age 18-70 years.
2. No chronic medical, neurological, psychiatric, renal, or cardiac disease.
3. Able to read and write.
4. Adequate cognition, hearing, vision, and physical ability.
Exclusion Criteria
1. Chronic liver disease.
2. Neuropsychiatric illness.
3. Use of psychoactive medications.
4. Illiteracy.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Sabry Thabit
Sohag , Akhmim, Schools street
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med--25-11-9MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.